Designed for the Clinic. Built for the Patient.

Immunogenik was founded with a mission to bring new hope to patients facing aggressive, difficult-to-treat cancers. Through innovative cell and antibody therapies, we aim to overcome tumor immune evasion and improve patient survival. Our lead program, 8R-70CAR T-cell therapy, is currently being evaluated in Phase I clinical trials.

We take every step with purpose — to prolong patients’ lives

Explore Technology & Pipeline→ Explore Clinical Trials→
The 8R-70 CAR design uniquely combines CD70 targeting with an IL-8 receptor to enhance tumor homing, persistence, and memory recall of CAR T cells within the tumor microenvironment, overcoming the greatest barriers to CAR T success in solid tumors.

8R-70CAR T-Cell Therapy

The 8R-70 CAR design uniquely combines CD70 targeting with an IL-8 receptor to enhance tumor homing, persistence, and memory recall of CAR T cells within the tumor microenvironment, overcoming the greatest barriers to CAR T success in solid tumors.

The humanized LAIR1 antibody blocks LAIR1, a critical immune checkpoint expressed on tumor-associated myeloid cells, reprogramming the tumor microenvironment to restore immune function and enhance antitumor efficacy.

LAIR1 Antibody Blockade

The humanized LAIR1 antibody blocks LAIR1, a critical immune checkpoint expressed on tumor-associated myeloid cells, reprogramming the tumor microenvironment to restore immune function and enhance antitumor efficacy.

A multifunctional CAR T-cell platform engineered to overcome tumor immune resistance by integrating antigen recognition, enhanced T-cell trafficking, and intrinsic immune checkpoint blockade.

3-in-1 CAR T-Cell Therapy

A multifunctional CAR T-cell platform engineered to overcome tumor immune resistance by integrating antigen recognition, enhanced T-cell trafficking, and intrinsic immune checkpoint blockade.

Connect and Partner with Us
The Immunogenik Story
Learn more about our mission to
defeat incurable cancers, and meet
the leaders making it happen.
Company
Latest News and Updates
Keep up with recent publications,
press releases, conferences, and more.
‍
News
See Current Openings
Interested in joining us?
Our team is growing!
Careers
Get in Touch!
Collaborator? Investor? Partner?
We would love to hear from you!
Contact
Immunotherapy Overview
Discover how immunotherapy is revolutionizing cancer treatment.
CAR T Cells
CAR T-cell therapy has shown remarkable success in patients with cancer, including those who did not respond to standard treatments or who relapsed after prior therapy.
TCR-Modified T Cells
TCR-modified T-cell therapy is an emerging approach that harnesses a patient’s immune system to recognize and attack cancer cells with greater precision.
Immune Checkpoint Blockades
Immune checkpoint blockade targets natural regulatory pathways that normally restrain immune activity, unleashing anti-tumor responses that have proven effective against multiple aggressive cancers.

By clicking "Agree", you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Agree